Eli Lilly & Co. (LLY)
1172.20
+15.47
(+1.34%)
USD |
NYSE |
Sep 01, 11:21
Eli Lilly Research and Development Expense (Annual) : 13.34B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 13.34B |
| December 31, 2024 | 10.99B |
| December 31, 2023 | 9.313B |
| December 31, 2022 | 7.191B |
| December 31, 2021 | 7.026B |
| December 31, 2020 | 6.086B |
| December 31, 2019 | 5.595B |
| December 31, 2018 | 5.051B |
| December 31, 2017 | 5.282B |
| December 31, 2016 | 5.244B |
| December 31, 2015 | 4.796B |
| December 31, 2014 | 4.734B |
| December 31, 2013 | 5.531B |
| December 31, 2012 | 5.278B |
| December 31, 2011 | 5.021B |
| December 31, 2010 | 4.884B |
| December 31, 2009 | 4.326B |
| December 31, 2008 | 3.841B |
| December 31, 2007 | 3.487B |
| December 31, 2006 | 3.129B |
| December 31, 2005 | 3.026B |
| December 31, 2004 | 2.691B |
| December 31, 2003 | 2.350B |
| Date | Value |
|---|---|
| December 31, 2002 | 2.149B |
| December 31, 2001 | 2.235B |
| December 31, 2000 | 2.018B |
| December 31, 1999 | 1.784B |
| December 31, 1998 | 1.739B |
| December 31, 1997 | 1.382B |
| December 31, 1996 | 1.190B |
| December 31, 1995 | 1.042B |
| December 31, 1994 | 897.10M |
| December 31, 1993 | 954.60M |
| December 31, 1992 | 924.90M |
| December 31, 1991 | 766.90M |
| December 31, 1990 | 702.70M |
| December 31, 1989 | 605.40M |
| December 31, 1988 | 540.80M |
| December 31, 1987 | 466.30M |
| December 31, 1986 | 427.00M |
| December 31, 1985 | 369.80M |
| December 31, 1984 | 341.40M |
| December 31, 1983 | 293.60M |
| December 31, 1982 | 267.36M |
| December 31, 1981 | 234.81M |
| December 31, 1980 | 200.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 14.83B |
| Merck & Co., Inc. | 12.51B |
| Pfizer Inc. | 10.25B |
| Bristol Myers Squibb Co. | 9.492B |
| Atai Beckley, Inc. | 53.06M |